Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Part of paid clinical trials in San Francisco, California.

Sponsor
CytoDyn, Inc.
Study ID
NCT04504942
Phase
PHASE2
Status
Completed

Conditions

  • Solid Tumor, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A single arm phase II study with 30 patients of leronlimab (PRO 140) in patients with CCR5+ locally advanced or metastatic solid tumors.

Key Dates

Start date
May 1, 2020
Status verified
Sep 2021
Primary completion
Nov 7, 2021
Completion
Jan 27, 2025

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Leronlimab 525mg
    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Primary Outcome Measure

Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). [ Time Frame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Quest Clinical ResearchSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By research site
Quest Clinical Research· San Francisco, CA

Related Studies